Calquence

Calquence is a cancer medicine used in adults to treat: - chronic lymphocytic leukaemia (CLL), a blood cancer affecting B cells (a type of white blood cell). In patients who have not had previous treatment for CLL, Calquence may be used on its own or combined with another cancer medicine, obinutuzumab. It may also be  used with venetoclax, another cancer treatment, with or without obinutuzumab. In patients with CLL who have had previous treatment, Calquence is used on its own (monotherapy); - mantle cell lymphoma (MCL), a blood cancer affecting B cells. Calquence is used on its own in patients whose MCL has come back (relapsed) or not responded (refractory) to treatment and who have not received treatment with a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor. It is also used in combination with other cancer medicines, bendamustine and rituximab, in adults with previously untreated MCL who cannot have an autologous stem cell transplantation (ASCT). An ASCT is a procedure where the patient’s bone marrow is replaced by their own stem cells to form new bone marrow that produces healthy cells. Calquence contains the active substance acalabrutinib.